TFF1 antibody (C-Term)

Catalog No. ABIN3026542

The Mouse Monoclonal anti-TFF1 antibody (Clone GE2) (ABIN3026542) specifically detects TFF1 in IHC (p). The antibody is reactive with Human samples.

Quick Overview for TFF1 antibody (C-Term) (ABIN3026542)

Target: TFF1 (Trefoil Factor 1 (TFF1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TFF1 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: GE2

Product Details anti-TFF1 Antibody

Binding Specificity: AA 57-84, C-Term

Purpose: Estrogen Inducible Protein pS2 Antibody / TFF1 (azide and preservative free)

Sequence: CFDDTVRGVP WCFYPNTIDV PPEEECEF

Characteristics: This antibody recognizes a polypeptide of ~6.5 kDa, identified as Estrogen Inducible Protein pS2. The antibody's epitope is localized between amino acids 57-84. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intrachain disulfide bonds, forming the trefoil motif, or P-domain. Estrogen Inducible Protein pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60 % of breast carcinomas are positive for estrogen inducible protein pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. It is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that estrogen inducible protein pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.

Purification: Protein G affinity chromatography

Immunogen: Amino acids CFDDTVRGVPWCFYPNTIDVPPEEECEF (57-84) from the C-terminus of human Estrogen Inducible Protein pS2 was used as the immunogen for this antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the Estrogen Inducible Protein pS2 antibody to be titered up or down for optimal performance.

1. Staining of FFPE tissues REQUIRES digestion with Pronase E at 1 mg/mL in PBS for 15 min at 37oC. Heat Induced Epitope Retrieval is not suitable for this antibody.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the Estrogen Inducible Protein pS2 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for TFF1

Target: TFF1 (Trefoil Factor 1 (TFF1))

Alternative Name: Estrogen Inducible Protein pS2

Background: This antibody recognizes a polypeptide of ~6.5 kDa, identified as Estrogen Inducible Protein pS2. The antibody's epitope is localized between amino acids 57-84. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intrachain disulfide bonds, forming the trefoil motif, or P-domain. Estrogen Inducible Protein pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60 % of breast carcinomas are positive for estrogen inducible protein pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. It is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that estrogen inducible protein pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.

Pathways: EGFR Signaling Pathway